PATENT CLAIM ANALYSIS

Application Number: 16088397
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["544", "343000"]

Abstract:
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Claim (Index 9):
A method for the treatment or prophylaxis of a central nervous system disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to  claim 1 , in free or pharmaceutically acceptable salt form.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 97.0
- Lexical Diversity: 1.30769
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14394467', '15629481', '14627968', '14777466', '16056143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7782089191472819
- 35 USC 102 Novelty (BERT): 0.5445867308096171
- Combined Prediction Score: 0.7548467003135154
- Mean Citation Score: 383.6470800000001
- Max Citation Score: 401.85004
- Similarity Product: 295.94646859347336

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test